Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) released its quarterly earnings results on Thursday, August 14th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01), Zacks reports.
Oramed Pharmaceuticals Stock Down 0.5%
Shares of Oramed Pharmaceuticals stock traded down $0.01 during trading on Thursday, reaching $2.06. The company's stock had a trading volume of 52,840 shares, compared to its average volume of 69,631. Oramed Pharmaceuticals has a 12-month low of $1.82 and a 12-month high of $3.09. The business has a 50 day moving average price of $2.14 and a 200-day moving average price of $2.21.
Institutional Trading of Oramed Pharmaceuticals
An institutional investor recently raised its position in Oramed Pharmaceuticals stock. Jane Street Group LLC lifted its holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 35.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,173 shares of the biotechnology company's stock after buying an additional 17,510 shares during the quarter. Jane Street Group LLC owned 0.16% of Oramed Pharmaceuticals worth $144,000 as of its most recent SEC filing. 12.73% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Separately, Wall Street Zen lowered Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has a consensus rating of "Hold".
Get Our Latest Stock Report on ORMP
Oramed Pharmaceuticals Company Profile
(
Get Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Further Reading
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
